Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Ting Han

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5134549034. Sources: OpenAlex.

Their work

Papers
15 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2015: 1 paper · 2016: 4 papers · 2017: 3 papers · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 15

  1. Human Pancreatic Cancer Organoids. Co-author DOI 10.1111/cpr.70210↗
  2. A phase I study of the safety and activity of K-001 in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12885-021-08375-6↗
  3. Caveolin-2 is regulated by BRD4 and contributes to cell growth in pancreatic cancer. First author DOI 10.1186/s12935-020-1135-0↗
  4. Coordinated silencing of the Sp1-mediated long noncoding RNA MEG3 by EZH2 and HDAC3 as a prognostic factor in pancreatic ductal adenocarcinoma. Co-author DOI 10.20892/j.issn.2095-3941.2019.0427↗
  5. JQ1 effectively inhibits vasculogenic mimicry of pancreatic ductal adenocarcinoma cells via the ERK1/2-MMP-2/9 signaling pathway both in vitro and in vivo. Co-author PMID 30899402↗
  6. A novel feedback loop between high MALAT-1 and low miR-200c-3p promotes cell migration and invasion in pancreatic ductal adenocarcinoma and is predictive of po… Co-author DOI 10.1186/s12885-018-4954-9↗
  7. Synergistic effects of the combination of 5-Aza‑CdR and suberoylanilide hydroxamic acid on the anticancer property of pancreatic cancer. Co-author DOI 10.3892/or.2017.6059↗
  8. Elevated COX-2 Expression Promotes Angiogenesis Through EGFR/p38-MAPK/Sp1-Dependent Signalling in Pancreatic Cancer. First author DOI 10.1038/s41598-017-00288-4↗
  9. Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancrea… Co-author DOI 10.18632/oncotarget.14069↗
  10. Correlated high expression of FXR and Sp1 in cancer cells confers a poor prognosis for pancreatic cancer: A study based on TCGA and tissue microarray. Co-author DOI 10.18632/oncotarget.16633↗
  11. The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer. Co-author DOI 10.1007/s13277-015-4741-z↗
  12. EZH2 promotes cell migration and invasion but not alters cell proliferation by suppressing E-cadherin, partly through association with MALAT-1 in pancreatic ca… Co-author DOI 10.18632/oncotarget.7156↗
  13. Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer. Co-author DOI 10.18632/oncotarget.7663↗
  14. Sp1 and COX2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.8593↗
  15. Functional significance of macrophages in pancreatic cancer biology. Co-author DOI 10.1007/s13277-015-4127-2↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Feng Jiao · 14 shared papers, 2015–2021 · strength 1.21
  2. Meng Zhuo · 11 shared papers, 2016–2020 · strength 0.96
  3. Jiujie Cui · 7 shared papers, 2017–2021 · strength 0.71
  4. Hai Xia Hu · 9 shared papers, 2015–2019 · strength 0.68
  5. Liwei Wang · 7 shared papers, 2016–2017 · strength 0.47
  6. Liwei Wang · 4 shared papers, 2015–2020 · strength 0.40
  7. Liwei Wang · 2 shared papers, 2018–2020 · strength 0.22
  8. Lei Wang · 3 shared papers, 2016–2017 · strength 0.20
  9. Xianming Kong · 1 shared paper, 2026 · strength 0.18
  10. Aina He · 1 shared paper, 2026 · strength 0.18
  11. Xiaoguang Wang · 1 shared paper, 2026 · strength 0.18
  12. Zunqiang Zhou · 1 shared paper, 2026 · strength 0.18
  13. Chunyan Dong · 1 shared paper, 2026 · strength 0.18
  14. Dongxi Xiang · 1 shared paper, 2026 · strength 0.18
  15. Haiyan Yang · 2 shared papers, 2016–2021 · strength 0.18
  16. Leilei Wu · 2 shared papers, 2017 · strength 0.14
  17. Junjie Hang · 2 shared papers, 2016 · strength 0.13
  18. Yiyi Liang · 1 shared paper, 2020 · strength 0.13
  19. Tiebo Mao · 1 shared paper, 2021 · strength 0.11
  20. Liwei Wang · 1 shared paper, 2021 · strength 0.11
  21. Jiong Hu · 1 shared paper, 2021 · strength 0.11
  22. Yu Wang · 1 shared paper, 2021 · strength 0.11
  23. Yu Wang · 1 shared paper, 2017 · strength 0.08
  24. Lixia Wu · 1 shared paper, 2017 · strength 0.07
  25. Weifeng Song · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.